Related Experiment Video
Updated: Apr 9, 2026
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
3.5K
Cerebrolysin for acute ischaemic stroke
Liliya Eugenevna Ziganshina1, Tatyana Abakumova
1Department of Basic and Clinical Pharmacology, Kazan (Volga region) Federal University, 18 Kremlevskaya Street, 420008, 14-15 Malaya Krasnaya Street, 420015, Kazan, Tatarstan, Russian Federation.
The Cochrane Database of Systematic Reviews
|June 18, 2015
Summary
Cerebrolysin, a pig brain-derived peptide mixture, shows no proven benefit for acute ischemic stroke treatment. Current evidence from randomized controlled trials (RCTs) is insufficient to support its routine use in stroke patients.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Cerebrolysin, a peptide and amino acid mixture from porcine brain tissue, possesses potential neuroprotective and neurotrophic properties.
- It is frequently administered for acute ischemic stroke in Asian and post-Soviet nations.
Purpose of the Study:
- To evaluate the efficacy and safety of Cerebrolysin in acute ischemic stroke patients.
- To synthesize evidence from randomized controlled trials (RCTs) regarding Cerebrolysin's use in acute ischemic stroke.
Main Methods:
- Comprehensive literature search across multiple databases (Cochrane, MEDLINE, EMBASE, etc.) up to November 2014.
- Inclusion of randomized controlled trials comparing Cerebrolysin (initiated within 48 hours, duration ≥2 weeks) against placebo or no treatment.
- Independent data extraction and risk of bias assessment by two reviewers.
Main Results:
- One trial with 146 participants met the inclusion criteria, exhibiting a high risk of bias across several domains.
- No significant differences were observed in mortality (RR 0.87, 95% CI 0.29-2.58) or adverse events (RR 1.62, 95% CI 0.69-3.82) between Cerebrolysin and placebo groups.
- Trial funding and drug provision by the manufacturer raised concerns about potential bias.
Conclusions:
- The existing randomized controlled trial evidence does not support the routine use of Cerebrolysin for treating acute ischemic stroke.
- Further high-quality, independent research is needed to definitively establish Cerebrolysin's role in stroke management.
